Measurement of Beta Cell Death in Individuals With Cystic Fibrosis

Status Completed

Clinical Trial Summary

This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants will have a blood sample drawn in order to measure the levels of differentially methylated insulin DNA.

Clinical Trial Description

Cystic fibrosis related diabetes (CFRD) causes increased morbidity and mortality in people with cystic fibrosis (CF). The prevalence of CFRD increases with age. While CFRD is diagnosed in only 2 percent of children under 10 year sof age, it is present in 19 percent of adolescents and up to 50 percent of adults with CF. Although CFRD is uncommon in children, recent animal and human studies have shown that milder glycemic abnormalities are common in infants and young children with CF. One of the proposed mechanisms for early glucose dysregulation in CF is related to ongoing beta cell death that may start at a very early age. The assay to be used in this study measures differentially methylated insulin DNA, released exclusively by beta cells, to determine levels of beta cell death. This assay has been shown to detect beta cell death in individuals at risk of developing type 1 diabetes. If this assay successfully detects beta cell death in individuals with CF, the investigators can identify critical time points of beta cell loss in people with CF. Understanding how and when glycemic dysregulation occurs in CF will lead to better treatment of CFRD in the future. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03713437
Study type	Observational
Source	University of Nebraska
Contact
Status	Completed
Phase
Start date	April 4, 2019
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02723968` - Cystic Fibrosis Related Diabetes Screening.	N/A
Completed	`NCT04503408` - A Comparison of Clinical Parameters in With and Without Abnormal Glucose Tolerance.
Recruiting	`NCT05723445` - The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes	N/A
Completed	`NCT04519853` - A Pilot Study of a Low Glycemic Load Diet in Adults With Cystic Fibrosis	N/A
Terminated	`NCT03234387` - A CFit Study - Baseline
Completed	`NCT03227094` - Simplification of CF-related Diabetes Screening at Home	N/A
Completed	`NCT03961516` - Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
Terminated	`NCT03237767` - A CFit Study - Acute Exercise	N/A
Withdrawn	`NCT05229640` - Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis	N/A
Active, not recruiting	`NCT04533646` - Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes	Phase 4
Recruiting	`NCT05766774` - FEED-Cystic Fibrosis (FEED-CF)	N/A
Not yet recruiting	`NCT06449677` - Bionic Pancreas in CFRD	Phase 3
Terminated	`NCT03939065` - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management	N/A
Completed	`NCT02810691` - The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis	N/A
Recruiting	`NCT05568134` - Alternate Measures of Glucose During OGTT Testing for CFRD
Recruiting	`NCT05463289` - ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2	N/A
Not yet recruiting	`NCT04379726` - β-cell Function and Insulin Sensitivity in Patients With Cystic Fibrosis
Completed	`NCT03650712` - EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis	N/A
Active, not recruiting	`NCT06084468` - Cardiac Structure and Function in Patients With Cystic Fibrosis
Recruiting	`NCT04530383` - Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes	Phase 2